Cargando…
Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC
BACKGROUND: High circulating levels of cellular adhesion molecules (CAMs) in non‐small cell lung cancer (NSCLC) have been supposed to act as a negative prognostic factor. Here, we explored the predictive role of pre‐treatment levels of CAMs in previously treated patients receiving nivolumab for NSCL...
Autores principales: | Carbone, Federico, Ministrini, Stefano, Bonaventura, Aldo, Vecchié, Alessandra, Minetti, Silvia, Bardi, Nicholas, Elia, Edoardo, Ansaldo, Anna Maria, Ferrara, Daniele, Rijavec, Erika, Dal Bello, Maria Giovanna, Biello, Federico, Rossi, Giovanni, Tagliamento, Marco, Alama, Angela, Coco, Simona, Spallarossa, Paolo, Grossi, Francesco, Genova, Carlo, Montecucco, Fabrizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286788/ https://www.ncbi.nlm.nih.gov/pubmed/34390488 http://dx.doi.org/10.1111/eci.13668 |
Ejemplares similares
-
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
por: Dal Bello, M. G., et al.
Publicado: (2019) -
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
por: Alama, Angela, et al.
Publicado: (2019) -
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Genova, Carlo, et al.
Publicado: (2019) -
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
por: Ottonello, Selene, et al.
Publicado: (2020) -
Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System
por: Truini, Anna, et al.
Publicado: (2014)